Pulmonary embolism (PE) is caused by emboli, which have originated from venous thrombi, travelling to and occluding the arteries of the lung. PE is the most dangerous form of venous thromboembolism, ...

Group 1 pulmonary hypertension (or pulmonary arterial hypertension) is a rare, highly complex, and progressive disorder that is incurable and ultimately can lead to premature death. PAH causes ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

BOSTON, MA—There are more encouraging signs that pulmonary artery denervation may one day bring relief to patients who have pulmonary arterial hypertension (PAH) due to left heart disease. At the late ...

Dr. Samir Zaidi (Medicine): A 48-year-old woman with a history of venous thromboembolism was seen in the pulmonary clinic of this hospital because of cough and decreased exercise tolerance. Fifteen ...

Jagged-2, a signaling protein, may be a potential therapeutic target for slowing or halting the progression of PAH, according ...

The placement of a Swan-Ganz catheter allows specialists to diagnose or test for major heart issues without requiring you to undergo major surgery. Usually, it’s a diagnostic tool for people in ...

The Division of Pulmonary, Critical Care and Sleep Medicine at Saint Louis University School of Medicine offers a three-year combined ACGME-accredited comprehensive subspecialty training program that ...